Sunesis Pharmaceuticals, Inc.’s (SNSS) share price has entered into oversold territory with an RSI value of 29.2. The Zacks Consensus Estimate on Sunesis Pharmaceuticals, Inc.’s earnings for the full year period has profit of 0.09 cents over the past two months to $-0.72 per share. Currently, Sunesis Pharmaceuticals, Inc. is a Zacks #2 Rank (“Buy”), suggesting that now might be a good time to get in on (SNSS) after its recent drop.
SUNESIS PHARMACEUTICALS INC NEW (SNSS): Free Stock Analysis Report
Zacks Investment Research
- Health Care Industry
- Personal Investing Ideas & Strategies